Abstract
Hepatocellular carcinoma (HCC) is a chemoresistant tumor that frequently expresses a high level of p 170 glycoprotein of the multidrug-resistance (MDR) gene. Preliminary data suggested that VP-16 showed modest activity in HCC. Recently, schedule-dependent cytotoxicity of VP-16 has been demonstrated. In this study, we tested the therapeutic efficacy of chronic oral VP-16 plus tamoxifen, a potential MDR-reversing agent, in patients with far-advanced HCC. A prospective single-arm study was conducted in the National Taiwan University Hospital. To be eligible, patients must have had unresectable and non-embolizable HCC, objectively measurable tumors, adequate hemogram with absolute granulocyte count greater than or equal to 2,000/mm3, and platelet count greater than or equal to 1x10 (5)/mm3, total serum bilirubin less than or equal to 3.0 mg/dl, age less than or equal to 75 years, and a Karnofsky performance status of greater then or equal to 50%. The treatment included VP-16 (Bristol-Myers-Squibb, Princeton, NJ), 50 mg/m2/day, orally, Days 1 to 21, and tamoxifen (Pharmachemie B.V. Haarlem, Netherlands), 40 mg/day, orally, Days 1 to 21; repeated every 5 weeks. Between December 1990 and December 1993, a total of 33 patients were enro...Continue Reading
References
Jan 1, 1977·British Journal of Haematology·J Palek
Feb 19, 1992·Journal of the National Cancer Institute·C C HuangJ R Gu
Dec 2, 1992·Journal of the National Cancer Institute·D L TrumpR L Fine
Jun 15, 1990·Cancer·P F EngstromA Schutt
Oct 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D H JohnsonJ D Hainsworth
Sep 29, 1989·Biochemical and Biophysical Research Communications·E BignonY Nishizuka
Mar 1, 1988·Cancer Treatment Reviews·S R NerenstoneM A Friedman
Apr 1, 1989·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J ErdsteinS Mishkin
Oct 1, 1981·European Journal of Cancer & Clinical Oncology·F CavalliH H Hansen
Jan 15, 1983·Cancer·W M MeliaR Williams
Jan 13, 1984·Biochemical and Biophysical Research Communications·H Y Lam
Nov 8, 1984·The New England Journal of Medicine·P Narasimhan
Aug 15, 1981·Cancer·C FabianE Hearne
Jun 1, 1995·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·E K ManesisS J Hadziyannis
Jan 15, 1995·Cancer·E BaralI Berczi
Jan 1, 1994·Oncology·M J MillwardB M Cantwell
Jul 1, 1993·Cancer·S NoguchiH Koyama
Citations
Nov 11, 2010·BMC Cancer·Winnie YeoSheng-Long Ye
Jun 8, 2012·The Oncologist·Zhong-Zhe LinAnn-Lii Cheng
Dec 8, 2009·Current Problems in Surgery·Charles H ChaSharon M Weber
Nov 13, 2007·Journal of Gastroenterology and Hepatology·Jae-Lyun LeeYoon-Koo Kang
Dec 29, 1998·Human Pathology·C CohenP B DeRose
Jun 16, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Anna K NowakMichael Findlay
Feb 24, 2001·Clinics in Liver Disease·A Aguayo, Y Z Patt
May 13, 2015·Biochimica Et Biophysica Acta·Samy A F Morad, Myles C Cabot
Jan 4, 1998·Journal of Gastroenterology and Hepatology·D Y LinY F Liaw
Aug 1, 1997·Journal of Gastroenterology and Hepatology·Y Y ChouH C Hsu
Jan 6, 2001·Arquivos De Gastroenterologia·V P Conte
Sep 5, 2002·Cancer·Hao ZhangKyosuke Yamamoto
Jun 18, 1999·Journal of Clinical Gastroenterology·S SavastanoG P Feltrin